Update on the management of inflammatory breast cancer

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
The Oncologist (Impact Factor: 4.87). 02/2003; 8(2):141-8.
Source: PubMed


Inflammatory breast cancer (IBC) is the most aggressive manifestation of primary breast carcinoma, with the clinical and biological characteristics of a rapidly proliferating disease. The multidisciplinary management of IBC has changed in the past 3 decades and is presently clearly outlined in sequence, with preoperative or neoadjuvant chemotherapy representing the mainstay of treatment. Anthracyclines and taxanes are the most effective cytotoxic agents in the management of primary breast cancer and should be the standard of treatment for women with IBC. Locoregional treatment includes radiotherapy with or without surgery and continues to play a major role after appropriate medical treatment. The many investigations into the particular molecular determinants of IBC development have provided several interesting new therapeutic targets. Combination regimens that include angiogenic modulators, farnesyl transferase inhibitors, and p53 modulators hold great promise in the medical management of IBC. Future therapeutic approaches should focus on these discoveries so that we can improve the overall prognosis for women with IBC.

5 Reads
  • Source
    • "Moreover, the study compared between biological markers of the established in vitro emboli and patient emboli. Results showed that in vitro emboli express epithelial marker E-cadherin and RhoC-GTPase similar to patient emboli [13]. Authors concluded that the newly established model might provide an ideal model ''to accurately grow and study inflammatory breast cancer biology'' [43]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammatory breast cancer (IBC) is a highly metastatic and fatal form of breast cancer. In fact, IBC is characterized by specific morphological, phenotypic, and biological properties that distinguish it from non-IBC. The aggressive behavior of IBC being more common among young women and the low survival rate alarmed researchers to explore the disease biology. Despite the basic and translational studies needed to understand IBC disease biology and identify specific biomarkers, studies are limited by few available IBC cell lines, experimental models, and paucity of patient samples. Above all, in the last decade, researchers were able to identify new factors that may play a crucial role in IBC progression. Among identified factors are cytokines, chemokines, growth factors, and proteases. In addition, viral infection was also suggested to participate in the etiology of IBC disease. In this review, we present novel factors suggested by different studies to contribute to the etiology of IBC and the proposed new therapeutic insights.
    Journal of Advanced Research 06/2013; 5(5). DOI:10.1016/j.jare.2013.06.004
  • Source
    • "Besides carcinomas and sarcomas, an uncommon and aggressive neoplasm in bitches is inflammatory carcinoma (IMC) [42], which is characterized by an inflammatory process of the breast gland [34]. As in humans [49] [50], animal IMC is characterized by a high rate of nodal and widespread metastasis [34] [41], particular aggressiveness [51], fulminant clinical course, and unfavourable prognosis [52]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tyrosine kinase receptors (TKRs) play a key role in tumour cell proliferation and survival since they are involved in endothelial cell activation leading to tumour neoangiogenesis. In particular, vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (c-KitR), and colony-stimulating factor 1 (CSF-1) are overexpressed or constitutively activated in human and pet malignancies. A variety of small molecule inhibitors targeting specific tyrosine kinases (known as tyrosine kinase inhibitors or TKIs) have recently been approved, or are under investigation, for the treatment of human cancer. TKI application in animal cancer is however relatively recent. This review aims to illustrate the major aspects of tyrosine kinase dysfunctions, with special regard to human and animal cancer of the mammary gland, providing an update on the background of the anti-angiogenic and anti-neoplastic properties of TKIs in human and veterinary cancer.
    Critical reviews in oncology/hematology 06/2013; 88(2). DOI:10.1016/j.critrevonc.2013.05.009 · 4.03 Impact Factor
  • Source
    • "Inflammatory Breast Cancer (IBC), a particularly lethal subset of locally advanced breast cancer, is currently estimated to affect up to 6% of breast cancer patients in the United States [2]. While most non-IBCs are detected by the presence of a dense mass in the mammary tissue , IBC is characterized by rapidly progressing primary skin changes such as erythema, skin thickening, peau d'aurange, and nipple retraction [2] [3]. The unique appearance of IBC is due to tumor emboli that readily metastasize into and block the dermal lymphatic vessels of the skin overlying the breast [4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although there are many subtypes of breast cancer, inflammatory breast cancer (IBC) is arguably the deadliest. Research over the past decade has demonstrated that IBC is a distinct entity from other forms of breast cancer. Important risk factors that have been associated with the development of aggressive breast cancers, such as IBC, include obesity and diet, which are evident in the United States, where the overconsumption of high-fat foods continues to contribute to obesity in the nation. Here we investigate differences in cholesterol uptake and storage between IBC, non-IBC, and mammary epithelial cell lines. Our results demonstrate that compared with human mammary epithelial cells (HMECs), both IBC and non-IBC cells have increased cholesterol content. IBC cells retain intracellular cholesterol esters, free cholesterol, and triglycerides in lipid-deficient environments. In contrast, we observe in cell-type-of-origin-matched non-IBC a significant decrease in lipid content under the same lipid-deficient conditions. These data suggest that cholesterol storage may be affected by the cholesterol content of the environment where the tumor cell was isolated. Here, we suggest that breast cancer cells may migrate when they are unable to obtain cholesterol from their extracellular environments.
    12/2012; 2012:412581. DOI:10.1155/2012/412581
Show more


5 Reads
Available from